You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 5,714,667


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,714,667
Title: Mice lacking expression of CTLA-4 receptor
Abstract:Disclosed is a mouse in which expression of the gene encoding the CTLA-4 receptor is suppressed. Also disclosed is a nucleic acid construct useful in preparing such a mouse, and a cell line containing such construct.
Inventor(s): Waterhouse; Paul David (London, CA), Mak; Tak Wah (Toronto, CA)
Assignee: Amgen Canada Inc. (Mississauga, CA)
Application Number:08/554,133
Patent Claims:1. A transgenic mouse homozygous for a disrupted CTLA-4 receptor gene, wherein said CTLA-4 receptor gene is disrupted by a selectable marker sequence introduced into said mouse or an ancestor of said mouse at an embryonic stage, and wherein said disrupted CTLA-4 receptor gene results in said mouse exhibiting enlarged lymph nodes as compared to a wild type mouse.

2. A mouse of claim 1, wherein the disruption results in a null mutation of the gene encoding a CTLA-4 receptor.

3. A CTLA-4 receptor DNA knockout construct comprising a selectable marker sequence flanked by DNA sequences homologous to the CTLA-4 receptor gene, wherein when said construct is introduced into a mouse or an ancestor of a mouse at an embryonic stage, said selectable marker sequence disrupts the CTLA-4 receptor gene in said mouse and results in said mouse exhibiting enlarged lymph nodes as compared to a wild type mouse.

4. A vector comprising the CTLA-4 receptor DNA knockout construct of claim 3.

5. A CTLA-4 receptor DNA knockout construct according to claim 3, wherein said construct consists of, 5' to 3', a thymidine kinase cassette; the CTLA-4 receptor fragment 1 containing exon 1 and most of intron 1 as depicted in FIG. 1; a neo cassette; and the CTLA-4 receptor fragment 2 containing the 3' half of exon 3, all of intron 3, and most of exon 4 as depicted in FIG. 1.

6. A mouse E14 embryonic stem cell line comprising the CTLA-4 DNA receptor knockout construct of claim 3.

Details for Patent 5,714,667

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2039-02-26
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2039-02-26
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.